Skip to content Skip to footer
Subscribe Now
NEWS

Basilea Pharmaceutica Enters Into a Licensing Deal with Venatorx Pharmaceuticals

Shots: Basilea Pharmaceutica entered into an exclusive license deal with Venatorx Pharmaceuticals to acquire global rights to ceftibuten-ledaborbactam etzadroxil, a P-III oral beta-lactam/beta-lactamase inhibitor (BL/BLI) combination for complicated urinary tract infections (cUTI), incl. pyelonephritis Under the agreement, Venatorx will receive an upfront payment along with potential milestone payments in 2025 and will also be eligible…
August 14, 2025

Read more

NEWS

Bayer Enters a ~$1.3B Deal with Kumquat Biosciences to Develop and Commercialize a KRAS G12D Inhibitor

Shots: Bayer has entered into an exclusive global license agreement & collaboration with Kumquat Biosciences to develop and commercialize its KRAS G12D inhibitor Kumquat will initiate & complete the P-Ia study following FDA’s IND clearance in Jul 2025, while Bayer handles further development & commercialization, with Kumquat holding an exclusive option to negotiate US profit-loss…
August 13, 2025

Read more

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (Aug 04, 2025 – Aug 08, 2025) 

This week, PharmaShots’ news was all about the updates on clinical trials, Regulatory, Pharma, MedTech, Biotech, M&A and Biosimilars. Check out our full report below:   Roche Reports P-III (Portal) Trial Data on Susvimo for Neovascular Age-Related Macular Degeneration (nAMD)  Read More: Roche   Ethris Reports First Patient Dosing in P-IIa Trial of ETH47 for Asthma  Read…
August 8, 2025

Read more

NEWS

DoveTree Medicines Enters a ~$5.99B Deal with XtalPi to Discover Novel Therapeutics Across Various Indications

Shots: XtalPi has entered into a strategic collaboration with DoveTree Medicines to identify novel therapeutics across oncology, immunology, inflammation, neurology, & metabolic diseases, leveraging XtalPi's de novo drug discovery platform As per the deal, DoveTree will gain exclusive global rights to develop & commercialize multiple therapeutics from the collaboration, in exchange for a $51M upfront,…
August 8, 2025

Read more

Knight Therapeutics and Incyte
NEWS

Knight Therapeutics and Incyte Expand Latin America Agreement to Include Retifanlimab and Axatilimab

Shots: Knight Therapeutics has amended its agreement with Incyte Biosciences to gain exclusive distribution rights for retifanlimab (Brand name: Zynyz in the US and EU) and axatilimab (Brand name: Niktimvo in the US) in LATAM Under the amended deal, Incyte will develop, manufacture, and supply retifanlimab and axatilimab, while Knight will handle regulatory approvals and…
August 6, 2025

Read more

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (Jul 28, 2025 – Aug 01, 2025)  

This week, PharmaShots’ news was all about the updates on clinical trials, Regulatory, Pharma, MedTech, Animal Health and Biosimilars. Check out our full report below:     Memo Therapeutics Reports P-II (SAFE KIDNEY II) Trial Data on Potravitug to Treat BKPyV Infection in Kidney Transplant Recipients  Read More: Memo therapeutics  Eli Lilly Reports Topline P-III (BRUIN…
August 1, 2025

Read more

NEWS

Madrigal Pharmaceuticals Signs a ~$2.1B Licensing Deal with CSPC Pharmaceutical for SYH2086

Shots: Madrigal has secured an exclusive global license from CSPC to develop, manufacture, & commercialize SYH2086 for advancing innovative combination therapies targeting MASH As per the deal, CSPC will receive $120M upfront & ~$2B in development, regulatory & commercial milestones, with net sales-based royalties; CSPC may also develop other oral GLP-1s in China under certain…
July 30, 2025

Read more

NEWS

Viridian Therapeutics Enters a ~$385M Deal with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan

Shots: Viridian & Kissei have entered into an exclusive collaboration & license agreement to develop & commercialize veligrotug & VRDN-003 in Japan As per the deal, Kissei will secure an exclusive license to develop & commercialize veligrotug & VRDN-003 in Japan, with the responsibility of all development, regulatory, & commercialization activities, & related costs in…
July 30, 2025

Read more

Load more